Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens
Michele Senni, John J.V. McMurray, Rolf Wachter, et al.
European Journal of Heart Failure (2016) Vol. 18, Iss. 9, pp. 1193-1202
Open Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez, David A. Morrow, Adam D. DeVore, et al.
New England Journal of Medicine (2018) Vol. 380, Iss. 6, pp. 539-548
Open Access | Times Cited: 1059
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
Thomas M. Maddox, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 6, pp. 772-810
Open Access | Times Cited: 757
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
Geetha Bolla, Bipul Sarma, Ashwini Nangia
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11514-11603
Closed Access | Times Cited: 327
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study
Rolf Wachter, Michele Senni, Jan Bělohlávek, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 8, pp. 998-1007
Open Access | Times Cited: 303
2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
Clyde W. Yancy, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2017) Vol. 71, Iss. 2, pp. 201-230
Closed Access | Times Cited: 263
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Böhm, Robin Young, Pardeep S. Jhund, et al.
European Heart Journal (2016) Vol. 38, Iss. 15, pp. 1132-1143
Open Access | Times Cited: 199
Accelerated and personalized therapy for heart failure with reduced ejection fraction
Li Shen, Pardeep Singh Jhund, Kieran F. Docherty, et al.
European Heart Journal (2022) Vol. 43, Iss. 27, pp. 2573-2587
Open Access | Times Cited: 80
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
Thomas M. Maddox, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 15, pp. 1444-1488
Closed Access | Times Cited: 70
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
Pardeep S. Jhund, John J.V. McMurray
Heart (2016) Vol. 102, Iss. 17, pp. 1342-1347
Open Access | Times Cited: 164
Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides
Emilia D’Elia, Attilio Iacovoni, Muthiah Vaduganathan, et al.
European Journal of Heart Failure (2017) Vol. 19, Iss. 6, pp. 710-717
Open Access | Times Cited: 151
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization
Aditi Bhagat, Stephen J. Greene, Muthiah Vaduganathan, et al.
JACC Heart Failure (2018) Vol. 7, Iss. 1, pp. 1-12
Open Access | Times Cited: 143
Sacubitril/Valsartan
Kieran F. Docherty, Muthiah Vaduganathan, Scott D. Solomon, et al.
JACC Heart Failure (2020) Vol. 8, Iss. 10, pp. 800-810
Open Access | Times Cited: 114
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Milton Packer, Stefan D. Anker, Javed Butler, et al.
European Heart Journal (2020) Vol. 42, Iss. 6, pp. 671-680
Open Access | Times Cited: 114
cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Andreas Friebe, Peter Sandner, Achim Schmidtko
Naunyn-Schmiedeberg s Archives of Pharmacology (2019) Vol. 393, Iss. 2, pp. 287-302
Open Access | Times Cited: 111
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients
Jennifer Cautela, Jean‐Michel Tartière, Alain Cohen‐Solal, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 8, pp. 1357-1365
Open Access | Times Cited: 100
Practical guidance on the use of sacubitril/valsartan for heart failure
Andrew J. Sauer, Robert T. Cole, Brian C. Jensen, et al.
Heart Failure Reviews (2018) Vol. 24, Iss. 2, pp. 167-176
Open Access | Times Cited: 89
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation
Hung‐Yu Chang, An-Ning Feng, Man-Cai Fong, et al.
Journal of Cardiology (2019) Vol. 74, Iss. 4, pp. 372-380
Open Access | Times Cited: 82
Neprilysin Inhibitors in Heart Failure
Biykem Bozkurt, Ajith Nair, Arunima Misra, et al.
JACC Basic to Translational Science (2022) Vol. 8, Iss. 1, pp. 88-105
Open Access | Times Cited: 63
Reactive Oxygen Species Induced Pathways in Heart Failure Pathogenesis and Potential Therapeutic Strategies
Aušra Mongirdienė, L Skrodenis, Leila Varoneckaitė, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 602-602
Open Access | Times Cited: 44
Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations)
Przemyslaw Rajzer, Jan Biegus
Heart Failure Reviews (2025)
Open Access | Times Cited: 1
Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF
Nina Nouhravesh, Alexander Gunn, Derek D. Cyr, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
Enzyme‐Inspired Chiral Secondary‐Phosphine‐Oxide Ligand with Dual Noncovalent Interactions for Asymmetric Hydrogenation
Caiyou Chen, Zhefan Zhang, Shicheng Jin, et al.
Angewandte Chemie International Edition (2017) Vol. 56, Iss. 24, pp. 6808-6812
Closed Access | Times Cited: 69
Impact of systolic blood pressure on the safety and tolerability of initiating and up‐titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study
Michele Senni, John J.V. McMurray, Rolf Wachter, et al.
European Journal of Heart Failure (2017) Vol. 20, Iss. 3, pp. 491-500
Open Access | Times Cited: 69
What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan?
Pierpaolo Pellicori, Alessia Urbinati, Parin Shah, et al.
European Journal of Heart Failure (2017) Vol. 19, Iss. 6, pp. 768-778
Open Access | Times Cited: 65
Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany
Rolf Wachter, Ana Filipa Fonseca, Bogdan Balas, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 5, pp. 588-597
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top